Notice of Proposed Sale · 144
MoonLake Immunotherapeutics
MLTXNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- MoonLake Immunotherapeutics
- Issuer CIK
- 0001821586
- SEC file number
- 001-39630
- Phone
- 41 41 510 8022
- Person for whose account securities are to be sold
- Reich Kristian
- Relationships to issuer
- Officer
- Street
- DORFSTRASSE 29
- City
- ZUG
- State / country code
- V8
- Postal code
- 6300
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Class A Ordinary | 150,000 | 2,916,000.00 | 73,615,396 | 07/15/2026 | Nasdaq | UBS Financial Services, Inc. |
Broker / market maker — proposed row 1, entry 1
- Name
- UBS Financial Services, Inc.
- Street
- Eleven Madison Avenue
- Street (continued)
- 4th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10010
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Class A Ordinary | 04/05/2023 | Exchange of shares | Issuer | 150,000 | N | 04/05/2023 | NA |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| Jerucon Beratungsgesellschaft mbH | Common | 06/16/2026 | 50,000 | 934,995.00 |
| Jerucon Beratungsgesellschaft mbH | Common | 06/17/2026 | 50,000 | 971,325.00 |
| Jerucon Beratungsgesellschaft mbH | Common | 06/15/2026 | 50,000 | 944,280.00 |
Seller — prior-sale row 1, entry 1
- Name
- Jerucon Beratungsgesellschaft mbH
- Street
- Dorfstrasse 29
- City
- Zug
- State / country code
- V8
- Postal code
- 6300
Seller — prior-sale row 2, entry 1
- Name
- Jerucon Beratungsgesellschaft mbH
- Street
- Dorfstrasse 29
- City
- Zug
- State / country code
- V8
- Postal code
- 6300
Seller — prior-sale row 3, entry 1
- Name
- Jerucon Beratungsgesellschaft mbH
- Street
- Dorfstrasse 29
- City
- Zug
- State / country code
- V8
- Postal code
- 6300
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Remarks
150,000 shares represented in this filing are being sold under Jerucon Beratungsgesellschaft mbH
Notice signature
- Notice date
- 07/15/2026
- Signed
- /s/ UBS Financial Services Inc, as attorney-in-fact for Dr.Kristian Reich
- Plan adoption dates
- 03/10/2026
Company context
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company unlocking the potential of sonelokimab, a novel investigational Nanobody® for the treatment of inflammatory disease, to revolutionize outcomes for patients. Sonelokimab inhibits IL-17A and IL-17F by inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation. The Company’s focus is on inflammatory diseases with a major unmet need, including hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis and palmoplantar pustulosis - conditions affecting millions of people worldwide with a large need for improved treatment options. MoonLake was founded in 2021 and is headquartered in Zug, Switzerland. Further information is available at www.moonlaketx.com.